Amivantamab plus chemotherapy in a patient with osimertinib-resistant NSCLC with EGFR ex21 L858R mutation
28 Nov 2025
byDr. Molly Li, Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong
A 37-year-old female non-smoker was diagnosed in 2023 with stage IV non-small-cell lung cancer (NSÂCLC) harbouring EGFR exon 21 L858R mutation. Lymph node (LN), lung and bone metastases were present, and her Eastern Cooperative Oncology Group (ECOG) performance status was 0. IniÂtially, the patient’s response to standard-of-care first-line osimertinib, a third-genÂeration EGFR tyrosine kinase inhibitor (TKI), was good.1 A PET scan after 6–8 months showed that the metastases had shrunk in response to treatment. However, oligoprogression was also obÂserved at the primary lung tumour site, which was treated with radiotherapy.
